特寶生物(688278.SH)前三季度淨利潤預增55.07%到56.63%
格隆匯10月23日丨特寶生物(688278.SH)公佈,預計2022年前三季度實現歸屬於母公司所有者的淨利潤為1.98億元到2億元,與上年同期相比,預計將增加7031.17萬元到7231.17萬元,同比增加55.07%到56.63%。
公司預計2022年前三季度歸屬於母公司所有者扣除非經常性損益後的淨利潤為2.41億元到2.43億元,與上年同期相比,預計將增加8225.88萬元到8425.88萬元,同比增加51.82%到53.08%。
報吿期內公司積極開拓市場,派格賓等主營業務產品的銷售收入持續上升,淨利潤實現穩步增長。
報吿期內公益捐贈、收到的政府補助較去年同期都有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.